A Phase 1 randomized, double-blind, placebo controlled dose escalation clinical trial to evaluate the safety and immunogenicity of recombinant adenovirus serotype 26 HIV-1 vaccine (ad26.ENVA.01) in healthy, HIV-1 uninfected adults.

Trial Profile

A Phase 1 randomized, double-blind, placebo controlled dose escalation clinical trial to evaluate the safety and immunogenicity of recombinant adenovirus serotype 26 HIV-1 vaccine (ad26.ENVA.01) in healthy, HIV-1 uninfected adults.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2016

At a glance

  • Drugs HIV vaccine Ad26 ENVA-01 (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Most Recent Events

    • 31 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 05 Mar 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Oct 2010 to 1 Jul 2011.
    • 05 Mar 2015 According to the ClinicalTrials.gov record, planned primary completion date changed to 1 Jul 2011.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top